The Low Carb Diabetic

Promoting a low carb high fat lifestyle for the safe control of diabetes. Eat whole fresh food, more drugs are not the answer.


Welcome to the Low Carb Diabetic forum,have you signed up yet? if not then sign up and join us in the low carb community today!

    NICE approves PCSK9 inhibitor Repatha

    Share
    avatar
    graham64
    Member

    Status :
    Online
    Offline

    Male Posts : 2855
    Join date : 2014-08-10
    Location : Lancs

    NICE approves PCSK9 inhibitor Repatha

    Post by graham64 on Tue Feb 09 2016, 21:57

    The National Institute for Health and Care Excellence has taken a u-turn on its decision to bar NHS patients from access to Amgen’s cholesterol buster Repatha, the world’s first approved PCSK9 inhibitor.
     
    European regulators approved the drug last year for patients with uncontrolled cholesterol, after clinical data showed that it cut low-density lipoprotein-cholesterol (LDL-C) by some 55%-75% versus a placebo, and by around 35% to 45% compared with ezetimibe (Merck & Co’s Zetia)

    But the cost regulator sparked outrage when it issued draft guidelines rejecting Repatha (evolocumab) for NHS patients with high cholesterol and mixed dyslipidaemia, because of a lack of clinical trials measuring its direct effect on cardiovascular events and uncertainty over whether the drug would actually reduce angina, heart attacks and strokes.
     
    However, in a revised appraisal consultation document, NICE is now backing Repatha, alone or in combination with other lipid-lowering therapies, as an option in various scenarios, but only at a dosage of 140mg every two weeks and as long as the company continues to offer discount agreed in the patient access scheme.
     
    The Institute is supporting use of Repatha in patients with primary non-familial hypercholesterolaemia or mixed dyslipidaemia with progressive cardiovascular disease (CVD), who also have persistently high LDL-C concentrations despite maximum lipid-lowering therapy and can’t take statin therapy.
     
    Patients with primary heterozygous-familial hypercholesterolaemia or mixed dyslipidaemia with progressive, symptomatic CVD and persistently high LDL-C concentrations despite maximum lipid-lowering therapy also stand to gain access to the drug, as do those with severe primary heterozygous-familial hypercholesterolaemia or mixed dyslipidaemia without CVD, if they continue to have high levels of cholesterol despite maximum lipid-lowering therapy and can’t take statins.
     
    Amgen has welcomed NICE’s decision. “NICE has reviewed the technical responses to its initial appraisal, listened to patients and healthcare professionals and proposed a recommendation for the use of Repatha by the NHS in England and Wales,” said Tony Patrikios, Executive Medical Director, Amgen UK & Ireland.
     
    “However, beyond these draft recommendations, another priority will be patients with existing cardiovascular disease who fail to reduce their LDL-C to a satisfactory level despite the use of statins and who remain at high risk. For them, access to new treatment options is critically important to help avoid a heart attack or stroke,” he stressed.
     
    More than seven million people in the UK take statins daily to help them lower LDL cholesterol in the blood, but a significant number report side effects such as joint pain, fatigue, and nausea and, according to Amgen, in up to 60% of cases statins alone are not enough to control high cholesterol.
     
    Repatha’s annual cost per patient comes in at around £4,448.60 for 140mg every two weeks, and £6123.60 for 420 mg monthly.

    http://www.pharmatimes.com/Article/16-02-08/NICE_u-turn_backs_use_of_Amgen_s_Repatha.aspx



    Funny how years of denials by Big Pharma about side effects from statins all of a sudden there is a significant number of reported side effects.


    _________________
    I'm a skinny T2 diagnosed 4/4/2008, a high calorie LCHF diet and one metformin a day A1c 6.2 and no complications.

    Proving the LowCarb sceptics wrong for over nine years,

    Not all cherubs are Angels  Wink nor all diabetics Bonkers  Rolling Eyes
    avatar
    chris c
    Member

    Status :
    Online
    Offline

    Posts : 3003
    Join date : 2015-07-26

    Re: NICE approves PCSK9 inhibitor Repatha

    Post by chris c on Thu Feb 11 2016, 19:18

    "Amgen has welcomed NICE’s decision. “NICE has reviewed the technical responses to its initial appraisal, listened to patients and healthcare professionals and proposed a recommendation for the use of Repatha by the NHS in England and Wales,” said Tony Patrikios, Executive Medical Director, Amgen UK & Ireland."


    in other words, brown envelopes have changed hands

      Current date/time is Fri Jul 21 2017, 09:28